Clinical Trial: Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Biochemically Recurrent Prostate Carcinoma
Study Type: INTERVENTIONAL
Official Title: Phase 1 Trial to Determine Safety and Feasibility in Treating Biochemical Recurrence Post-Prostatectomy With PSMA PET Guided External Beam Radiotherapy Followed by Consolidative Radioligand Therapy
Brief Summary:
This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 [177Lu-rhPSMA-10.1])after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided external beam radiotherapy in treating post-prostatectomy patients with prostate cancer that has come back after a period of improvement (recurrent).In this study, radioligand therapy is a radioactive drug called 177Lu-rhPSMA-10.1.It works by binding to PSMA-expressing prostate tumor cells and…
Read more